Mahmoud Ould-Kaci

Combination of Oxaliplatin Plus Irinotecan in Patients With Gastrointestinal Tumors: Results of Two Independent Phase I Studies With Pharmacokinetics

Ernesto Wasserman, C. Cuvier, François Lokiec et al. · Journal of Clinical Oncology · 1999 · 134 citations

Afatinib alone or afatinib plus vinorelbine versus investigator's choice of treatment for HER2-positive breast cancer with progressive brain metastases after trastuzumab, lapatinib, or both (LUX-Breast 3): a randomised, open-label, multicentre, phase 2 trial

Javier Cortés, Véronique Dièras, Jungsil Ro et al. · The Lancet Oncology · 2015 · 126 citations · Full text

Breast Oncology, Oncology, Health Sciences +8

Randomized phase II study evaluating oxaliplatin alone, oxaliplatin combined with infusional 5-FU, and infusional 5-FU alone in advanced pancreatic carcinoma patients

Michel Ducreux, Emmanuel Mitry, Mahmoud Ould-Kaci et al. · Annals of Oncology · 2004 · 114 citations

Pancreatic Cancer, Gastrointestinal Oncology, Medicine +9

Vaccination of prostatectomized prostate cancer patients in biochemical relapse, with autologous dendritic cells pulsed with recombinant human PSA

Benoı̂t Barrou, G Benoît, Mahmoud Ould-Kaci et al. · Cancer Immunology Immunotherapy · 2004 · 75 citations · Full text

Vaccination, Recombinant Human Psa, Urology +8

Subcutaneous Interleukin-2 and Interferon Alfa Administration in Patients With Metastatic Renal Cell Carcinoma: Final Results of SCAPP III, a Large, Multicenter, Phase II, Nonrandomized Study With Sequential Analysis Design—The Subcutaneous Administration Propeukin Program Cooperative Group

Jean‐Marc Tourani, Christian Pfister, Mahmoud Ould-Kaci et al. · Journal of Clinical Oncology · 2003 · 44 citations